Pharnext (ALPHA.PA) Stock Price, Forecast & Analysis
Europe - EPA:ALPHA - FR001400N1P4 - Common Stock
ALPHA.PA Key Statistics, Chart & Performance
The current stock price of ALPHA.PA is 0.0002 EUR. In the past month the price decreased by -33.33%. In the past year, price decreased by -100%.
ALPHA.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 73.08 | 48.01B | ||
| 1AE.DE | ARGENX SE | 72.09 | 47.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | 24.38 | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| ALCLS.PA | CELLECTIS | N/A | 341.61M |
Related stock screener links
About ALPHA.PA
Company Profile
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
Company Info
Pharnext
14 rue de la Republique
Suresnes ILE-DE-FRANCE FR
Employees: 0
Phone: 33141092230
Pharnext / ALPHA.PA FAQ
What does Pharnext do?
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
Can you provide the latest stock price for Pharnext?
The current stock price of ALPHA.PA is 0.0002 EUR. The price increased by 100% in the last trading session.
Does ALPHA stock pay dividends?
ALPHA.PA does not pay a dividend.
What is the ChartMill rating of Pharnext stock?
ALPHA.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does Pharnext have?
Pharnext (ALPHA.PA) currently has 0 employees.
Who owns Pharnext?
You can find the ownership structure of Pharnext (ALPHA.PA) on the Ownership tab.
ALPHA.PA Technical Analysis
ALPHA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALPHA.PA. ALPHA.PA may be in some trouble as it scores bad on both profitability and health.
ALPHA.PA Financial Highlights
Over the last trailing twelve months ALPHA.PA reported a non-GAAP Earnings per Share(EPS) of -26278826.88. The EPS increased by 99.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -627.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPHA.PA Forecast & Estimates
9 analysts have analysed ALPHA.PA and the average price target is 12750 EUR. This implies a price increase of 6374999900% is expected in the next year compared to the current price of 0.0002.
For the next year, analysts expect an EPS growth of 99.81% and a revenue growth -22.9% for ALPHA.PA